REGENERON PHARMACEUTICALS INC Form 8-K August 01, 2007

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2007 REGENERON PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter)

New York

000-19034

13-3444607

(State or other jurisdiction of (Commission File No.) IRS Employer Identification No.) Incorporation)

777 Old Saw Mill River Road, Tarrytown, New York 10591-6707

(Address of principal executive offices, including zip code)

(914) 347-7000

(Registrant s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02 Results of Operations and Financial Condition.

On August 1, 2007, Regeneron Pharmaceuticals, Inc. issued a press release announcing its financial and operating results for the quarter ended June 30, 2007. The press release is being furnished to the Securities and Exchange Commission pursuant to Item 2.02 of Form 8-K and is attached as Exhibit 99.1 to this Form 8-K.

<u>Item 9.01</u> Financial Statements and Exhibits.

(d) Exhibits

99.1 Press Release dated August 1, 2007.

Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 8-K

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

REGENERON PHARMACEUTICALS, INC.

Date: August 1, 2007

By: /s/ Stuart Kolinski Name: Stuart Kolinski Title: Senior Vice President and General Counsel

Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 8-K

Exhibit Index

Number Description

99.1 Press Release dated August 1, 2007.